Despite months of biopharma industry pushback, the European Commission has unconditionally approved Novo Holdings’ $16.5 billion acquisition of Catalent.
The Federal Trade …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.